Editas delays IND for Allergan-partnered CRISPR program – FierceBiotech
FierceBiotech |
Editas delays IND for Allergan-partnered CRISPR program
FierceBiotech Editas Medicine has delayed the target date for filing an IND for its lead candidate. The setback to the Allergan-partnered CRISPR program stems from delays at a third-party manufacturer working on leber congenital amaurosis (LCA) treatment LCA10. Editas Medicine Inc (NASDAQ:EDIT) reported earnings of ($0.85) per share missing Walls Streets expectations. Editas Medicine Announces First Quarter 2017 Results and Update Editas Medicine Inc (EDIT) Releases Earnings Results |
